FDA Seeks Clearer Rules For Use Of Osteoporosis Meds

Law360, New York (September 9, 2011, 2:22 PM EDT) -- A U.S. Food and Drug Administration advisory panel on Friday recommended that makers of certain osteoporosis drugs associated with jaw disorders and leg fractures should clarify on labels how long the drugs should be used, but did not specify the correct length of time.

The panel voted 17-6 in favor of having drug manufacturers change the language on labels and package inserts to better instruct patients on the recommended duration of use, but did not suggest how the wording of the directions should be changed, the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.